| pubmed-article:9621257 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C1518999 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C0882849 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C0300926 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C1516084 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:9621257 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:9621257 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9621257 | pubmed:dateCreated | 1998-8-14 | lld:pubmed |
| pubmed-article:9621257 | pubmed:abstractText | The purpose of this study was to determine the effectiveness of second mobilization strategies in patients who yielded < 2.5 x 10(6) CD34+ PBSC/kg after initial mobilization. Repeat mobilization attempts were made with chemotherapy and G-CSF (n = 61) or G-CSF alone (n = 58) in patients who failed initial mobilization with chemotherapy and G-CSF (n = 92) or G-CSF alone (n = 27). A median of 0.27 x 10(6) CD34+ cells/kg per apheresis was collected after the second mobilization, compared with 0.16 with initial harvests (p = 0.0001). Forty-eight percent achieved a target CD34+ cell dose > or = 2.5 x 10(6)/kg when harvests from the first and second mobilizations were combined. Fifteen of 17 patients (88%) with > or = 1.5 x 10(6) CD34+ cells/kg harvested after first mobilization had > or = 2.5 x 10(6) CD34+ cells/kg collected when first and second harvests were combined, as compared with 42 of 102 (41%) achieving < 1.5 x 10(6) CD34+ cells/kg with first PBSC harvests (p = 0.0001). Second mobilizations with chemotherapy and G-CSF or G-CSF alone resulted in similar CD34+ cell yields. Toxicities of second mobilizations were comparable with those of first mobilizations. Seventy-nine patients (66%) received high-dose chemotherapy with PBSC support, with recovery of neutrophils and platelets in a median of 11 and 15 days, respectively. Transplant-related mortality was 4%, and event-free survival at 2 years was 0.34. It was concluded that second mobilization attempts in patients who fail to achieve > or = 2.5 x 10(6) CD34+ cells/kg on initial mobilization were successful in 48% of patients. G-CSF alone was as effective as chemotherapy plus G-CSF in mobilizing CD34+ cells and was associated with less morbidity. | lld:pubmed |
| pubmed-article:9621257 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9621257 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9621257 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9621257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9621257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9621257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9621257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9621257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9621257 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9621257 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:9621257 | pubmed:issn | 1061-6128 | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:BucknerC DCD | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:AllenCC | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:SchwartzbergL... | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:HazeltonBB | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:LonginKK | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:TauerKK | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:ZhenBB | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:WeaverC HCH | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:LewkowLL | lld:pubmed |
| pubmed-article:9621257 | pubmed:author | pubmed-author:WeaverZZ | lld:pubmed |
| pubmed-article:9621257 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9621257 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:9621257 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9621257 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9621257 | pubmed:pagination | 241-9 | lld:pubmed |
| pubmed-article:9621257 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:meshHeading | pubmed-meshheading:9621257-... | lld:pubmed |
| pubmed-article:9621257 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9621257 | pubmed:articleTitle | Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. | lld:pubmed |
| pubmed-article:9621257 | pubmed:affiliation | Clinical Research Division of Response Oncology, Inc., Memphis, TN 38117, USA. | lld:pubmed |
| pubmed-article:9621257 | pubmed:publicationType | Journal Article | lld:pubmed |
